Assessment of MRD clinical trials

Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.

This study looks at how a specific treatment for multiple myeloma affects whether the cancer cells can be detected after two years. It compares stopping treatment after two years with continuing it, to see how this impacts patients who already have no detectable cancer cells.